GSK improves guidance as it adapts to life in slimmed down form

27 July 2022

UK pharma major GSK (LSE: GSK) has presented its first set of financial results since it spun off its consumer health division Haleon earlier this month.

The London-based drugmaker has raised its full-year revenue and profit guidance in presenting the figures, now predicting sales to grow between 6% and 8% in 2022, up from its prior forecast of 5% to 7%.

"New capacity and flexibility for GSK to invest in growth"GSK’s new guidance for adjusted operating profit growth is 13% to 15%, above its previous forecast of 12% to 14%.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK